Aldeyra's Reproxalap Faces FDA Rejection, Stock Plummets
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 11 2025
0mins
Source: TipRanks
Aldeyra Therapeutics Inc's stock plummeted approximately 75% in premarket trading as it hit a 52-week low following another FDA rejection of its lead drug reproxalap.
The FDA issued a Complete Response Letter indicating that the New Drug Application for reproxalap lacked substantial evidence of efficacy in treating dry eye disease, raising significant concerns about the reliability of clinical trial findings. This marks the third rejection for reproxalap, which has faced ongoing challenges in demonstrating effectiveness in controlled studies. Aldeyra plans to request a Type A meeting with the FDA to discuss the next steps for approval, which could have critical implications for its drug development strategy.
The repeated failures in obtaining FDA approval have led to extreme market pessimism regarding Aldeyra's future prospects, significantly impacting investor confidence and raising questions about the company's ability to secure future financing and continue its research efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALDX
Wall Street analysts forecast ALDX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 2.280
Low
9.00
Averages
9.50
High
10.00
Current: 2.280
Low
9.00
Averages
9.50
High
10.00
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Levicept Appoints New CFO to Drive Strategic Growth
- Executive Appointment: Levicept Ltd (ALDX) has appointed Darlene Deptula-Hicks as the new CFO, succeeding the departing Nicholas Stern, with this executive transition aimed at strengthening financial leadership to support future growth.
- Clinical Data Highlight: This appointment coincides with exceptional Phase II data for Levicept's lead candidate, LEVI-04, indicating the company's potential in the neurotrophin-3 inhibitor space, which may lay the groundwork for future market performance.
- Extensive Financial Experience: Deptula-Hicks brings decades of international financial leadership, having served as CFO at F-star Therapeutics, showcasing her deep background in both public and private life science markets, which is expected to enhance Levicept's strategic financial management.
- Multiple Board Roles: She currently holds board positions at Aldeyra Therapeutics and Lytix Biopharma, further amplifying her influence in the life sciences sector, which may support Levicept's strategic partnerships and market expansion.
See More
Levicept Appoints New Chief Financial Officer
- Executive Appointment: Levicept has appointed Darlene Deptula-Hicks as Chief Financial Officer, who brings extensive international experience in biotechnology and pharmaceuticals, having previously served as CFO at F-star Therapeutics where she successfully led an $85 million PIPE financing and Nasdaq listing.
- Clinical Trial Results: LEVI-04 has demonstrated significant pain relief and a good safety profile in a Phase II trial involving over 500 patients, highlighting its potential in treating osteoarthritis, with a market opportunity estimated to exceed $10 billion.
- Strategic Development: Darlene's appointment is expected to strengthen Levicept's senior team, supporting the company's strategic goals in the late-stage development of LEVI-04, aiming to provide a novel non-opioid therapeutic option for millions of osteoarthritis patients worldwide.
- Leadership Experience: With her extensive background in senior leadership roles across biotechnology, pharmaceuticals, and medical devices, Darlene is well-equipped to support the company through IPOs and major capital raises, potentially unlocking new growth opportunities for Levicept.
See More
Aldeyra Appoints New Board Member
- New Board Appointment: Aldeyra Therapeutics has appointed Darlene Deptula-Hicks to its board, bringing over 30 years of experience in biotechnology, which is expected to significantly enhance the company's strategic direction.
- Extensive Industry Background: Currently serving as CFO of Normunity Inc. and previously at F-star Therapeutics, Deptula-Hicks's expertise will aid Aldeyra in navigating financial and strategic challenges during potential product commercialization.
- Focus on Sustainable Growth: Deptula-Hicks expressed her eagerness to collaborate with the board and leadership team to drive Aldeyra's sustainable long-term growth, indicating a proactive approach to new product development and market expansion.
- Innovative Therapeutic Solutions: Aldeyra is dedicated to developing innovative therapies for immune-mediated diseases, with product candidates like reproxalap for dry eye disease and allergic conjunctivitis, showcasing the company's potential to address unmet medical needs.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ:ALDX) securities between November 3, 2023, and March 16, 2026, that May 29 is the critical deadline to apply as lead plaintiff, and failure to do so may result in loss of compensation rights.
- Fee Arrangement: Investors joining the Aldeyra class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden for investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made false and misleading statements during the class period, particularly regarding the inconsistent results of its drug candidate reproxalap's clinical trials, which led to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made misleading statements regarding inconsistent results from clinical trials, resulting in investor losses when the true information became public, highlighting significant deficiencies in the company's disclosure practices.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Aldeyra Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Aldeyra Therapeutics on behalf of investors who purchased securities between November 3, 2023, and March 16, 2026, indicating significant legal challenges that could impact the company's stock price and market confidence.
- Allegation Details: The lawsuit alleges that the defendants issued false and misleading statements and failed to disclose material adverse facts regarding Aldeyra's business and operations, particularly the inconsistency of reproxalap clinical trial results, which may have led to investor losses.
- Investor Rights Protection: Investors must apply by May 29, 2026, to be appointed as lead plaintiff in the lawsuit, highlighting the urgency of the legal process and its potential impact on investor decisions and future legal actions.
- Law Firm Background: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, underscoring its expertise and influence in protecting investor rights.
See More
Levicept Appoints New CFO to Drive Strategic Growth
- Executive Appointment: Levicept Ltd (ALDX) has appointed Darlene Deptula-Hicks as the new CFO, succeeding the departing Nicholas Stern, with this executive transition aimed at strengthening financial leadership to support future growth.
- Clinical Data Highlight: This appointment coincides with exceptional Phase II data for Levicept's lead candidate, LEVI-04, indicating the company's potential in the neurotrophin-3 inhibitor space, which may lay the groundwork for future market performance.
- Extensive Financial Experience: Deptula-Hicks brings decades of international financial leadership, having served as CFO at F-star Therapeutics, showcasing her deep background in both public and private life science markets, which is expected to enhance Levicept's strategic financial management.
- Multiple Board Roles: She currently holds board positions at Aldeyra Therapeutics and Lytix Biopharma, further amplifying her influence in the life sciences sector, which may support Levicept's strategic partnerships and market expansion.
See More
Levicept Appoints New Chief Financial Officer
- Executive Appointment: Levicept has appointed Darlene Deptula-Hicks as Chief Financial Officer, who brings extensive international experience in biotechnology and pharmaceuticals, having previously served as CFO at F-star Therapeutics where she successfully led an $85 million PIPE financing and Nasdaq listing.
- Clinical Trial Results: LEVI-04 has demonstrated significant pain relief and a good safety profile in a Phase II trial involving over 500 patients, highlighting its potential in treating osteoarthritis, with a market opportunity estimated to exceed $10 billion.
- Strategic Development: Darlene's appointment is expected to strengthen Levicept's senior team, supporting the company's strategic goals in the late-stage development of LEVI-04, aiming to provide a novel non-opioid therapeutic option for millions of osteoarthritis patients worldwide.
- Leadership Experience: With her extensive background in senior leadership roles across biotechnology, pharmaceuticals, and medical devices, Darlene is well-equipped to support the company through IPOs and major capital raises, potentially unlocking new growth opportunities for Levicept.
See More
Aldeyra Appoints New Board Member
- New Board Appointment: Aldeyra Therapeutics has appointed Darlene Deptula-Hicks to its board, bringing over 30 years of experience in biotechnology, which is expected to significantly enhance the company's strategic direction.
- Extensive Industry Background: Currently serving as CFO of Normunity Inc. and previously at F-star Therapeutics, Deptula-Hicks's expertise will aid Aldeyra in navigating financial and strategic challenges during potential product commercialization.
- Focus on Sustainable Growth: Deptula-Hicks expressed her eagerness to collaborate with the board and leadership team to drive Aldeyra's sustainable long-term growth, indicating a proactive approach to new product development and market expansion.
- Innovative Therapeutic Solutions: Aldeyra is dedicated to developing innovative therapies for immune-mediated diseases, with product candidates like reproxalap for dry eye disease and allergic conjunctivitis, showcasing the company's potential to address unmet medical needs.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ:ALDX) securities between November 3, 2023, and March 16, 2026, that May 29 is the critical deadline to apply as lead plaintiff, and failure to do so may result in loss of compensation rights.
- Fee Arrangement: Investors joining the Aldeyra class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, ensuring legal support without financial burden for investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made false and misleading statements during the class period, particularly regarding the inconsistent results of its drug candidate reproxalap's clinical trials, which led to investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is recognized for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that Aldeyra made misleading statements regarding inconsistent results from clinical trials, resulting in investor losses when the true information became public, highlighting significant deficiencies in the company's disclosure practices.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling such cases.
See More
Aldeyra Faces Class Action Lawsuit from Investors
- Class Action Initiated: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Aldeyra Therapeutics on behalf of investors who purchased securities between November 3, 2023, and March 16, 2026, indicating significant legal challenges that could impact the company's stock price and market confidence.
- Allegation Details: The lawsuit alleges that the defendants issued false and misleading statements and failed to disclose material adverse facts regarding Aldeyra's business and operations, particularly the inconsistency of reproxalap clinical trial results, which may have led to investor losses.
- Investor Rights Protection: Investors must apply by May 29, 2026, to be appointed as lead plaintiff in the lawsuit, highlighting the urgency of the legal process and its potential impact on investor decisions and future legal actions.
- Law Firm Background: Bragar Eagel & Squire, P.C. is a nationally recognized law firm specializing in securities, derivative, and commercial litigation, underscoring its expertise and influence in protecting investor rights.
See More
